Industry
A British medicinal cannabis company based on the Isle of Man is selling up to 25 per cent of its equity to patients in the UK, offering them the opportunity to invest in their business and become part-owners. This marks a significant step forward for the UK’s medicinal cannabis industry, which has faced numerous obstacles in recent years due to strict regulations and a lack of availability.
The company, called Kanabo, produces vaporizers and cannabis oils for medical use, which have been approved by the Israeli Ministry of Health. The products are designed to be used by patients with chronic pain, PTSD, epilepsy, and other conditions that can be treated with cannabis.
Kanabo’s move to offer equity to patients is part of a larger trend in the cannabis industry, which has seen a surge in investment in recent years. As more countries legalize cannabis for medical and recreational use, companies are looking for new ways to raise funds and expand their operations.
In the US, cannabis companies have been able to raise billions of dollars in funding through public offerings and private placements. In Canada, where cannabis is legal for both medical and recreational use, companies have also been able to raise significant capital through stock offerings.
The UK’s medicinal cannabis industry, however, has been slower to develop due to strict regulations and a lack of availability. Although cannabis was legalize for medicinal use in 2018, only a handful of products have been approved by the government, and patients have faced long waiting times and high costs to access them.
Kanabo’s decision to offer equity to patients is a response to these challenges, and could help to create a more patient-focused and sustainable industry. By giving patients a stake in the business, Kanabo is creating a sense of ownership and community, which could help to build trust and loyalty among its customers.
Of course, there are risks associated with investing in any business, and patients should carefully consider their options before investing in Kanabo. However, for those who are interested in the potential benefits of medical cannabis and want to support the growth of the industry, this could be a unique and exciting opportunity.
Overall, Kanabo’s decision to offer equity to patients is a positive development for the UK’s medicinal cannabis industry, and could help to create a more patient-focused and sustainable business model. As more companies explore new ways to raise funds and expand their operations, we can expect to see further innovation and growth in this exciting and rapidly-evolving industry.
